Cytek Biosciences, Inc. (NASDAQ:CTKB), a leading cell analysis solutions company, today announced that its Board of Directors has approved the repurchase of up to an aggregate of $50 million of its common stock, subject to compliance with applicable law. The Company’s common stock is listed on The Nasdaq Global Select Market under the symbol “CTKB”. The repurchase program will continue until the end of the fiscal year unless extended or shortened by the Board of Directors.
Any repurchases would be made in the open market and/or in privately negotiated transactions, and may be made from time to time or in one or more larger repurchases. The program will be conducted in compliance with the Securities and Exchange Commission’s Rule 10b-18 and applicable legal requirements. The amount and timing of any repurchases made under the repurchase program will depend on a variety of factors, including available liquidity, cash flow and market conditions.
The program does not obligate the Company to acquire any particular amount of our common stock and the program may be modified or suspended at any time at the Company’s discretion.
